By Pierre Bertrand

Merck KGaA said Friday that it has discontinued a Phase 2 trial for berzosertib in combination with topotecan in patients with relapsed, platinum-resistant small-cell lung cancer.

The German pharmaceuticals and chemicals company said that, following an interim analysis, the study was discontinued due to low probability of meeting the pre-defined objective of the trial.

"SCLC remains a difficult-to-treat disease, with minimal advances in the past 20 years," Merck said, adding that it will continue external studies exploring berzosertib in additional combinations and clinical settings.

Write to Pierre Bertrand at pierre.bertrand@wsj.com

(END) Dow Jones Newswires

June 03, 2022 10:06 ET (14:06 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
過去 株価チャート
から 5 2024 まで 6 2024 Merck KGaA (PK)のチャートをもっと見るにはこちらをクリック
Merck KGaA (PK) (USOTC:MKKGY)
過去 株価チャート
から 6 2023 まで 6 2024 Merck KGaA (PK)のチャートをもっと見るにはこちらをクリック